Skip to main content
logo
Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0100
+0.0040 (66.67%)
Apr 22, 2026, 4:00 PM EST

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $13.68M in the quarter ending June 30, 2025, a decrease of -89.33%. This brings the company's revenue in the last twelve months to $65.09M, down -53.99% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.

Revenue (ttm)
65.09M
Revenue Growth
-53.99%
P/S Ratio
0.06
Revenue / Employee
128.63K
Employees
506
Market Cap
3.98M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024178.03M117.75M195.34%
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
CASI Pharmaceuticals26.85M
Orgenesis1.04M
Vaccinex601.00K
GPL Holdings376.54K
ZIVO Bioscience209.03K
Oncology Pharma10.21K
Revenue Rankings

Adaptimmune Therapeutics News

More News